Low dose danazol in the treatment of the premenstrual syndrome

Miriam Deeny, Robert Hawthorn, D. M. Hart
In: Postgraduate Medical Journal · 1991 · vol. 67(787) , pp. 450–454 · doi:10.1136/pgmj.67.787.450 · W2168679403
article OA: bronze CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

A double-blind crossover study found that low-dose danazol significantly improved symptoms of severe premenstrual syndrome compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Summary This double-blind, randomized, crossover study compared the efficacy and safety of danazol (100 mg twice daily) with matching placebo in the treatment of severe premenstrual syndrome. Nineteen patients were randomly allocated to receive danazol for 3 months followed by placebo, and 18 to receive treatment in the reverse order. Assessments of overall condition showed improvement to be statistically significantly more likely with danazol than with placebo (P<0.001) after 3 months' treatment. Furthermore, daily visual analogue scale assessments demonstrated statistically significantly better premenstrual scores with danazol in comparison to placebo for breast discomfort, irritability, depression, anxiety, mood swings, crying, depressed libido and abdominal swelling. It is concluded that danazol provides effective and generally well tolerated treatment for severe premenstrual syndrome.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (2)

References (13)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T04:49:05.109227+00:00
License: CC0 · commercial use OK